3-Imidazol-1-yl-3-[4-[(6-methoxynaphthalen-2-yl)amino]phenyl]-2,2-dimethylpropanoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-Imidazol-1-yl-3-[4-[(6-methoxynaphthalen-2-yl)amino]phenyl]-2,2-dimethylpropanoic acid
• 英文别名: 3-imidazol-1-yl-3-[4-[(6-methoxynaphthalen-2-yl)amino]phenyl]-2,2-dimethylpropanoic acid
• 化学式: C₂₅H₂₅N₃O₃
• 分子量: 415.5
• InChiKey: ZMBSTUXDLPKKPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  76.4
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• COMPOSITIONS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES
  申请人：ANGION BIOMEDICA CORP.

  公开号：US20160038490A1

  公开（公告）日：2016-02-11

  Methods are provided for treating cancer and other dysproliferative diseases by administering to a subject in need there of a therapeutically effective amount of a synergistic composition comprising an HER2 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof; and a CYP26 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof; wherein said therapeutically effective amount suppresses the growth of dysproliferative cells in vivo. Compositions comprising a combination of an HER2 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof; and a CYP26 inhibitor a pharmaceutically acceptable salt or prodrug thereof are also described.
• [EN] COMPOSITIONS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE MALADIES DYSPROLIFÉRATIVES
  申请人：ANGION BIOMEDICA CORP

  公开号：WO2014015137A2

  公开（公告）日：2014-01-23

  Methods are provided for treating cancer and other dysproliferative diseases by administering to a subject in need there of a therapeutically effective amount of a synergistic composition comprising an HER2 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof; and a CYP26 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof; wherein said therapeutically effective amount suppresses the growth of dysproliferative cells in vivo. Compositions comprising a combination of an HER2 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof; and a CYP26 inhibitor a pharmaceutically acceptable salt or prodrug thereof are also described.